News
Empagliflozin Secures Reimbursement for Heart Failure Treatment
Starting May 1st, health insurance companies will cover Jardiance® (empagliflozin) for patients with heart failure with reduced ejection fraction. Cardiologists, pediatric cardiologists, angiologists, and internists will be able to prescribe it with reimbursement. This decision was made by the State Institute for Drug Control (SÚKL) in mid-April. Hundreds of thousands of Czechs suffering from this serious condition will now have access to another effective medication. The drug is manufactured by Boehringer Ingelheim.
Gut-Brain Axis − Future of MS Treatment?
The relationship between the gut microbiome and multiple sclerosis has been a major topic recently.…
Teriflunomide under the microscope in studies and practice
Not always do the conclusions from clinical studies fully confirm in real clinical practice. Does…
Is it possible to extend the life of diabetics thanks to modern treatment?
People aged 60 with type 2 diabetes are estimated to live on average 6-7 years less compared to…
Extract from Aloe barbadensis in the Treatment of Irritable Bowel Syndrome
The authors of a pooled analysis of two randomized controlled trials evaluated whether…
Updated Recommendations for Treatment of von Willebrand Disease
In 2021, new recommendations for the therapy of von Willebrand disease (vWD) were published, based…
Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of…
Brentuximab Vedotin in Patients with R/R cHL in the Real World: What to Expect?
How does brentuximab vedotin (BV) perform as maintenance therapy in real-world practice for…
What Response to the COVID-19 Vaccine Can Be Expected in Patients After Stem Cell Transplantation?
During the recent virtual congress of the European Society for Blood and Marrow Transplantation…
News in the Treatment of Allergic Rhinitis
According to literary sources, 17–28.5% of Europeans suffer from allergic rhinitis (AR), which…